Dosing Begins in Phase 3 PHOENIX Trial of AMX0035

Dosing Begins in Phase 3 PHOENIX Trial of AMX0035

311629

Dosing Begins in Phase 3 PHOENIX Trial of AMX0035

Amylyx Pharmaceuticals‘ global Phase 3 clinical trial investigating AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS) has begun dosing participants. The PHOENIX trial (NCT05021536) is expected to include 600 participants whose symptoms began in the past two years, which is a less-stringent criteria than was required for the smaller CENTAUR Phase 2 trial (NCT03127514). Enrollment will run across 65 clinical sites in the U.S. and Europe, as part of collaborations with the Northeast ALS Consortium (NEALS)…

You must be logged in to read/download the full post.